

5-1-2002

Forced expression of the interferon regulatory factor 2 oncoprotein causes polyploidy and cell death in FDC-P1 myeloid hematopoietic progenitor cells

Ronglin Xie

University of Massachusetts Medical School

Andre J. Van Wijnen

University of Massachusetts Medical School

Caroline M. J. van der Meijden

University of Massachusetts Medical School

See next page for additional authors

Follow this and additional works at: <http://escholarship.umassmed.edu/oapubs>

 Part of the [Cancer Biology Commons](#), [Medical Cell Biology Commons](#), and the [Oncology Commons](#)

Repository Citation

Xie, Ronglin; Van Wijnen, Andre J.; van der Meijden, Caroline M. J.; Stein, Janet L.; and Stein, Gary S., "Forced expression of the interferon regulatory factor 2 oncoprotein causes polyploidy and cell death in FDC-P1 myeloid hematopoietic progenitor cells" (2002). *Open Access Articles*. 361.

<http://escholarship.umassmed.edu/oapubs/361>

Forced expression of the interferon regulatory factor 2 oncoprotein causes polyploidy and cell death in FDC-P1 myeloid hematopoietic progenitor cells

Authors

Ronglin Xie, Andre J. Van Wijnen, Caroline M. J. van der Meijden, Janet L. Stein, and Gary S. Stein

Forced Expression of the Interferon Regulatory Factor 2 Oncoprotein Causes Polyploidy and Cell Death in FDC-P1 Myeloid Hematopoietic Progenitor Cells¹

Rong-Lin Xie, Andre J. van Wijnen, Caroline M. van der Meijden, Janet L. Stein, and Gary S. Stein²

Department of Cell Biology, University of Massachusetts Medical School, Worcester, Massachusetts 01655

ABSTRACT

The IFN regulatory factor-2 (IRF-2) oncoprotein controls the cell cycle-dependent expression of *histone H4* genes during S phase and may function as a component of an E2F-independent mechanism to regulate cell growth. To investigate the role of IRF-2 in control of cell proliferation, we have constructed a stable FDC-P1 cell line (F2) in which expression of IRF-2 is doxycycline (DOX)-inducible, and a control cell line (F0). Both the F2 and F0 cell lines were synchronized in the G₁ phase by isoleucine deprivation, and IRF-2 was induced by DOX on release of cells from the cell cycle block. Flow cytometric analyses indicated that forced expression of IRF-2 has limited effects on cell cycle progression before the first mitosis. However, continued cell growth in the presence of elevated IRF-2 levels results in polyploidy (>4n) or genomic disintegration (<2n) and cell death. Western blot analyses revealed that the levels of the cell cycle regulatory proteins cyclin B1 and the cyclin-dependent kinase (CDK)-inhibitory protein p27 are selectively increased. These changes occur concomitant with a significant elevation in the levels of the FAS-L protein, which is the ligand of the FAS (Apo1/CD95) receptor. We also found a subtle change in the ratio of the apoptosis-promoting Bax protein and the antiapoptotic Bcl-2 protein. Hence, IRF-2 induces a cell death response involving the Fas/FasL apoptotic pathway in FDC-P1 cells. Our data suggest that the IRF-2 oncoprotein regulates a critical cell cycle checkpoint that controls progression through G₂ and mitosis in FDC-P1 hematopoietic progenitor cells.

INTRODUCTION

IRF-2³ is a transcription factor with an important physiological role in cell growth regulation and IFN responsiveness (1–4). Our laboratory initially identified IRF-2 [also known as Histone Nuclear Factor-M (HiNF-M)] as a transcription factor that interacts with a phylogenetically conserved cell cycle regulatory element in the promoter of a DNA replication-dependent human *histone H4* gene (designated *FO108*, *H4/n*, or *H4FN*) that is up-regulated at the G₁-S phase transition in conjunction with DNA synthesis (5–13). IRF-2 is a repressor of IRF-1-dependent gene activation (1–4, 14–16). However, other studies have revealed that the protein is a modest activator of several genes, including *histone H4* (5, 6), *vascular cell adhesion molecule-1* (*VCAM-1*) (17), and *gp91phox* (18). IRF-2 contains a latent activation domain (19) and is a member of the winged helix-turn-helix family of transcription factors (20, 21). The activity of IRF-2 can be modulated by phosphorylation, acetylation, or interaction with coregulatory factors (22–25). The protein regulates transcription of its target genes at least in part by heterodimerization with

other IRFs, and by influencing the activity of large protein-DNA complexes (enhanceosomes; Refs. 6, 26–29).

Many genes up-regulated in late G₁ are involved in DNA synthesis and nucleotide metabolism and are controlled, at least in part, by the E2F class of transcription factors (30, 31). However, DNA replication-dependent histone genes represent an important exception to this rule. The majority of histone genes are transcriptionally controlled at the G₁-S phase transition and lack functional E2F binding sites (32, 33). Our previous studies have shown that cell cycle-controlled *histone H4* genes represent physiological and S phase-specific target genes for IRF factors (5, 6). Genetic ablation of IRF-2 abrogates the cell cycle-dependent up-regulation of *histone H4* gene expression (10). One question that arises is whether the IRF-dependent regulation of histone genes reflects broader participation of IRF factors in cell cycle control. We propose that IRF factors may regulate cell proliferation through transcriptional mechanisms that operate parallel to, and/or independent of, E2F proteins.

Several studies have shown that IRF-2 has properties of an oncoprotein. For example, IRF-2 can influence cell proliferation both in culture and *in vivo* and is capable of controlling cell cycle-regulatory proteins as well as DNA-replication-dependent histone genes (5, 34–39). IRF-2 also plays a key role in cell growth and differentiation of lymphocytes, and IRF-2 deficiency compromises development of natural killer and T helper type 1 cells (40–42). We have previously analyzed the regulation of IRF-2 and other histone gene transcription factors during the cell cycle in FDC-P1 myeloid progenitor cells to understand the role of IRF-2/HiNF-M in transcriptional control of gene expression at the G₁-S-phase transition (5, 43, 44). In this study, we directly tested the role of IRF-2 in regulating cell cycle progression by conditionally expressing IRF-2 in stable FDC-P1 cell lines. The principal result of our study is that forced expression of IRF-2 results in the abrogation of stringent cell growth control, reflected by the formation of polyploid cells and cell death. Our findings suggest that balanced physiological levels of IRF-2 are critical for normal cell growth regulation.

MATERIALS AND METHODS

Construction of a DOX-inducible IRF-2 Expression Vector. We prepared a conditional expression vector based on pRetroON (Clontech Laboratories, Inc., Palo Alto, CA) by cloning the full-length human IRF-2 coding sequence into the *Bam*HI restriction endonuclease site. The IRF-2 expression vector was derived from pcDNA/IRF-2 (2, 5); this vector contains a 1.4-kbp DNA fragment spanning the human IRF-2 coding sequence that was removed by *Bam*HI cleavage (New England Biolabs, Beverly, MA). The insert in the pRetroON/IRF-2 construct was subject to automated DNA sequencing (ABI model 377) to verify the start of the open reading frame and the orientation of the cDNA insert.

Cell Culture and Stable Transfection Experiments. Actively proliferating cultures of FDC-P1 cells (45) were maintained in RPMI 1640 medium with supplements (1% of IL-3-conditioned medium, 10% FCS, 100 units/ml penicillin, 100 μg/ml streptomycin, and 0.2 μM L-glutamine), at 37°C in humidified air containing 5% CO₂. RPMI 1640 and FCS were obtained from Life Technologies, Inc. (Grand Island, NY). Penicillin, streptomycin, and L-glutamine were purchased from Sigma Chemical Co. (St. Louis, MO). IL-3-

Received 11/29/01; accepted 2/27/02.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported in part by NIH Grants DK50222 and GM32010. The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

² To whom requests for reprints should be addressed, at Department of Cell Biology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655.

³ The abbreviations used are: IRF, IFN regulatory factor; DOX, doxycycline; IL, interleukin; FACS, fluorescence-activated cell sorting; CDK, cyclin-dependent kinase; FasL, Fas ligand.

conditioned medium was derived from WEHI-3B cells that produce and secrete IL-3 (46). The optimal amount of IL-3 for cytokine-dependent growth of FDC-P1 cells was empirically determined.

Experiments in which the DOX-inducible IRF-2 expression vector was transiently introduced into FDC-P1 cells were performed using the calcium phosphate-DNA precipitation method. Stable transfections with FDC-P1 cells were performed with 0.5 to 1.0 μg of pRetroON/IRF-2 expression construct or empty vector containing the puromycin gene as a positive selectable marker. Both plasmids were added into 0.15 ml of a 0.25 M CaCl_2 solution in a 1.5-ml sterile tube, and the solution was gently mixed. To this solution, we slowly added 0.15 ml of $2\times$ HEPES buffer (pH 7.11) and the CaCl_2 /DNA mixture was allowed to precipitate for 10 to 15 min at room temperature. FDC-P1 cells ($2\text{--}3 \times 10^6$ cells) were collected by centrifugation (1500 rpm, IEC centrifuge) in a 15-ml sterile tube (Corning Incorporated, Corning, NY). Cells were resuspended in 2.7 ml of complete RPMI 1640 containing 15 mM β -mercaptoethanol. Cell suspensions were mixed with the calcium/DNA precipitate followed by incubation for 5 min on ice, and then for 2 to 3 h at 37°C. The transfected FDC-P1 cells were washed twice with 15 ml of $1\times$ PBS. After transfection, cells were allowed to recover for 16 h and 0.4 $\mu\text{g}/\text{ml}$ puromycin was added to select for cells containing the pRetroON construct. Puromycin-resistant colonies were pooled to obtain two polyclonal cell lines containing either pRetroON/IRF-2 (F2 cells) or the parental pRetroON vector (F0 cells).

Cell Synchronization. F2 and F0 cells were synchronized by isoleucine deprivation, which arrests cells in G_1 phase. Actively growing cells (early-to-mid-log phase) were precultured for 30 h in isoleucine-deficient RPMI 1640 (Life Technologies, Inc.) with supplements. At time zero, cells were released from arrest by the addition of RPMI 1640 with supplements, with or without 25 ng/ml DOX (to induce IRF-2) for 72 h. Cells were harvested at selected time points for S1 nuclease protection assays, Western blot analysis, and FACS analysis.

S1 Nuclease Protection Assay. DNA oligonucleotides complementary to the mouse homologue of the human *FOI08 H4* gene and the mRNA coding sequence of the β -actin gene (internal control) were used as probes to monitor RNA levels as described previously (12). In brief, hybridization was performed overnight with each of the γ - ^{32}P -oligonucleotide probes (10 fmol) and 10 μg of RNA at 16°C in hybridization buffer [80% formamide, 100 mM sodium citrate, 300 mM sodium acetate, 1 mM EDTA (pH 6.4)]. S1 nuclease digestions were performed at 37°C for 40 min using 0.4 units of S1 nuclease per sample in 200 μl of S1 nuclease buffer [262.5 mM NaCl, freshly added 0.05 mg/ml BSA, 1 mM ZnCl_2 , 37.5 mM sodium acetate (pH 4.5)]. S1 protected DNA fragments were electrophoretically separated for 2 h at 60W in a 6% denaturing polyacrylamide gel (SequaGel), and signals were quantitated using the STORM B40 Scanner.

Flow Cytometric Analysis. At the indicated time points, F2 and F0 cells were harvested, washed with PBS, and fixed with 70% ethanol at -20°C for at least 2 h. Cells were harvested by centrifugation and resuspended in a buffer consisting of nine parts 0.05 M Na_2HPO_4 and one part 25 mM citric acid containing 0.1% Triton X-100 (pH 7.8). Samples were incubated for 30 min at 25°C to extract fragmented DNA (47). Cells were then washed with PBS and resuspended in 10 mM PIPES, 0.1 N NaCl, 2 mM MgCl_2 , and 0.1% Triton X-100, 20 $\mu\text{g}/\text{ml}$ propidium iodide (Sigma Chemical Co.), and 50 $\mu\text{g}/\text{ml}$ RNase A (pH 6.8), and incubated at room temperature for 30 min. The samples were analyzed for cell cycle phase distribution or ploidy and cell death by FACStar using the Consort 30 software (Becton Dickinson, Mountain View, CA).

Western Blot Analysis. Samples of F2 and F0 cells were harvested in parallel with those used for FACS analysis and subjected to Western blot analysis using the same methods that we described in detail previously (6). Equal amounts of total cellular protein were subjected to 10 or 12% SDS-PAGE. Proteins were transferred to polyvinylidene difluoride membranes (Immobilon-P; Millipore Corp., Bedford, MA). Blots were incubated overnight with primary antibodies using the indicated dilutions (α -IRF-2 at 1:3000, α -p53 at 1:1500, α -FAS-L at 1:1000, α -Bax and α -Bcl2 at 1:2000, α -cyclin A and α -cyclin B1 at 1:1500, α -CDK1 at 1:3000, α -CDK2 at 1:5000, α -p21 at 1:500–1000, α -p27 at 1:3500, and α -actin at 1:2500). Rabbit polyclonal antibodies (Fas-L, Bax, Bcl-2, CDK2, and p27), mouse monoclonal antibodies (p53, cyclin A, cyclin B1, and p21), and a goat polyclonal antibody (actin) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). The anti-IRF-2 polyclonal antibody was described previously (5). Blots were further incubated with diluted (1:8,000–10,000) horseradish peroxidase-

conjugated secondary antibodies (Santa Cruz Biotechnology, Inc.). Immuno-reactive protein bands were visualized by enhanced chemiluminescence detection (ECL kit; Amersham Pharmacia Biotech Inc., Piscataway, NJ). Signal intensities were quantitated by densitometry, and each experiment was repeated at least three times.


RESULTS

Elevation of IRF-2 Levels Up-Regulates *Histone H4* Gene Expression at the G_1 -S-Phase Transition. To examine the role of IRF-2 in regulating cell cycle progression, we prepared a stable FDC-P1 cell line containing an integrated DOX-responsive IRF-2 vector that permits forced expression of IRF-2 on DOX administration. FDC-P1 cells exhibit normal cell cycle control of histone gene transcription (43, 44); hence, the cell growth properties of FDC-P1 cells may approximate the phenotype of normal hematopoietic cells. We determined that low (*e.g.*, 1 pg/ml) and high (*e.g.*, 100 ng/ml) doses of DOX elevate IRF-2 levels to, respectively, 3- and 5-fold above normal endogenous IRF-2 levels. We also established that the IRF-2 construct mediates transcriptional activation of the *histone H4* gene promoter in a DOX-dependent manner (data not shown).

We assessed the effect of elevating IRF-2 levels on endogenous gene expression of a representative IRF-2-responsive target gene (*i.e.*, the mouse homologue of the DNA replication-dependent *histone H4/n* gene, also designated *H4.1*) that is normally induced at the G_1 -S-phase transition (12). FDC-P1 cells were synchronized by isoleucine deprivation (44, 48), and aliquots of cells were harvested at multiple time points after release from the cell-cycle blockade. Samples were analyzed by Western blot analysis to measure IRF-2 levels (Fig. 1, A and B) and by S1 nuclease protection analysis to assess endogenous H4 mRNA levels (Fig. 1, C and D). Western blot analysis shows that F2 cells containing the IRF-2 expression vector have higher levels of IRF-2 than F0 cells carrying the empty parental expression vector (Fig. 1A, compare rows 1 and 2 with rows 3 and 4). Furthermore, F2 cells cultured in the presence of DOX (25 ng/ml) express higher levels of IRF-2 than do F0 cells cultured in parallel under the same conditions (Fig. 1A, compare rows 1 and row 3). However, apart from these intended DOX-dependent differences in the levels of IRF-2, we note that IRF-2 protein levels are also regulated during the cell cycle irrespective of the presence of DOX (Fig. 1A, row 4), and that the presence of DOX has a modest stimulatory effect on endogenous IRF-2 levels (Fig. 1A, row 3). Thus, there are at least three factors that contribute to the steady-state levels of IRF-2 in synchronized FDC-P1 cells: presence of IRF-2 expression vector; cell cycle stage; and presence of DOX. However, quantitation of the Western blot signals (Fig. 1B) reveals that IRF-2 levels are consistently higher in F2 cells cultured in the presence of DOX than F2 cells cultured without DOX, or F0 cells that lack the IRF-2 expression construct. The DOX-dependent elevation of IRF-2 levels in F2 cells results in a significant increase in expression of the *histone H4/n* gene based on S1 nuclease protection analysis, and this effect on *H4/n* gene expression is not apparent in F2 cells cultured without DOX or in F0 cells (Fig. 1, C and D). We conclude that DOX elevates IRF-2 expression in F2 cells above physiological levels, with a functional effect on the expression of a cell cycle-controlled and IRF-2-responsive target gene.

Normal Cell Cycle Progression beyond the G_1 -S Phase Transition in FDC-P1 Cells Expressing Supraphysiological Levels of IRF-2. We analyzed whether elevation of IRF-2 levels during G_1 and the subsequent S phase affects cell cycle progression by evaluating the cell cycle distribution of FDC-P1 cells using FACS analysis (Fig. 2A). The F2 and F0 cell lines were synchronized by isoleucine deprivation and cultured in the presence or absence of DOX. The results show that the proportion of cells in S phase is very similar in F0 cells independent of

Fig. 1. Forced expression of IRF-2 up-regulates *histone H4* gene expression at the G₁-S-phase transition. A, Western blot analysis with an IRF-2 antibody using lysates from F2 and F0 cells at different times after release from synchronization in G₁ phase by isoleucine deprivation. IRF-2 expression was induced by DOX addition at 0 h (see Fig. 2B) +, induced with 25 ng/ml DOX; -, noninduced. B, quantitation of the Western blot data presented in A. C, S1 nuclease protection assay of RNA samples isolated at different times during cell cycle progression using radio-labeled oligonucleotides (*H4 probe* and *Actin probe*) detecting *histone H4* and actin mRNAs. *, the main S1 nuclease protected products for each probe, and either the mouse *H4.1* gene or the β -actin gene as described previously (12). D, graph showing the levels of *histone H4* mRNA normalized relative to β -actin mRNA in F0 and F2 cells in the absence (-) or presence (+) of DOX; quantitation of the S1 nuclease data from C was performed using a STORM B40 scanner.



the presence of DOX and in F2 cells grown in the absence of DOX at all of the time points examined between 4 and 16 h after cell cycle entry (Fig. 2B). The proportion of F2 cells in S phase seems to be modestly reduced in the presence of DOX (*i.e.*, ~10% decrease) relative to F2 cells grown without DOX or to F0 cells (Fig. 2B). We conclude that a small subset of IRF2-expressing cells may have lost the ability to enter S phase, perhaps because of a specific cell cycle block. However, the majority of F2 cells that express IRF2 at elevated levels retain the ability to progress unimpeded beyond the first G₁-S-phase transition.

Deregulated Expression of IRF-2 Causes Polyploidy and Cell Death in FDC-P1 Hematopoietic Progenitor Cells. We next assessed whether sustained elevation of IRF-2 in FDC-P1 cells influences cell growth-regulatory parameters and the cellular morphology of FDC-P1 cells (Figs. 3 and 4). The cell cycle distribution of F2 and F0 cells was analyzed by FACS in the presence or absence of DOX (Fig. 3). We validated that IRF-2 levels are only increased in F2 cells cultured in the presence of DOX and are not changed in F0 cells irrespective of the presence of DOX (Fig. 3A). For comparison, CDK2 levels were not altered in either F2 or F0 cells (Fig. 3A). The results

from FACS analysis reveal that continuous up-regulation of IRF-2 above normal endogenous levels for 2–3 days causes an increase in polyploid cells ($4n$ or $8n$; Fig. 3B, bottom row, right panel). Increased polyploidy occurs concomitantly with a decrease in the percentage of cells in S phase and an increase of cells in G₂-M (Fig. 3C). Apart from polyploidy (Fig. 3D), we also observed a significant fraction of cells with a genome content of less than $2n$ (Fig. 3, B, bottom row, right panel, and E). Microscopic examination of F2 cells cultured in the presence of DOX reveals many cells that are larger than normal (Fig. 4, right bottom panel), consistent with an increase in polyploid cells and/or cells in G₂-M phase. In addition, cell death is evident from an increase in small and partially fragmented cells in the same preparation (Fig. 4, right bottom panel). Taken together, our results indicate that deregulation of the level of IRF-2 alters the cell growth properties of FDC-P1 cells and results in polyploidy and cell death.

Forced Expression of IRF-2 in FDC-P1 Cells Elevates FAS-L, the Activating Component of the Fas/FasL Apoptotic Pathway. To understand the mechanism by which IRF-2 causes polyploidy and cell death in FDC-P1 cells, we performed Western blot analyses using

Fig. 2. Retention of competency for cell cycle progression through the first S-phase transition after forced expression of IRF-2. A, flow-cytometric analysis of F2 and F0 cell lines cultured in the presence (+) or absence (-) of DOX and analyzed at different times after release from isoleucine block. The graphs show the number of cells (vertical axis) with different DNA contents (horizontal axis) as measured by propidium iodide (PI). B, graph showing the percentage of F2 and F0 cells in S phase (vertical) in the presence or absence of DOX at different times (horizontal) during cell cycle traverse.





Fig. 3. Apoptosis and polyploidy of FDC-P1 cells during prolonged forced expression of IRF-2. F0 and F2 cells were synchronized and then cultured in conditioned medium (see "Materials and Methods") in the absence (-) or presence (+) of DOX for several days. *A*, Western blots showing a comparison of IRF-2 levels in F2 and F0 cells at the indicated days of treatment. CDK2 levels were monitored as internal control; forced IRF-2 expression does not cause a change in CDK2 protein levels. *B*, flow-cytometric assays reveal an increased proportion of cells exhibiting apoptosis or polyplody only in F2 cells in which IRF-2 levels are elevated by DOX induction, but not in noninduced F2 cells or F0 cells under inducing or noninducing conditions. *C*, graph showing the percentage of cells in the G₁, S phase, or G₂-M at day 3 after DOX administration in F0 and F2 cells. The percentage of F0 (squares) and F2 (circles) cells exhibiting polyplody (*D*) or undergoing apoptosis (*E*) at different days in culture in the presence (open symbols) or absence (closed symbols) of DOX. The graphs are based on results from at least three independent flow-cytometric assays.



antibodies against cell cycle regulatory proteins (*i.e.*, cyclins A and B1, CDK1, and CDK2, as well as the CDK inhibitors p27 and p21) and apoptosis-related factors (p53, FAS-L, Bax and Bcl-2; Fig. 5). As expected, DOX increased IRF-2 levels in F2 cells (Fig. 5A). We find that the levels of the cell cycle-regulatory proteins cyclin B1 and the CDK-inhibitory protein p27 are selectively increased after DOX enhancement of IRF-2 levels (Fig. 5B). However, in the same cells, there are no appreciable differences in the levels of CDK1 (CDC2), CDK2, and cyclin A, whereas the CDK-inhibitory protein p21 is not detected (Fig. 5B). The selective increase in the levels of cyclin B1 and p27 indicate that forced expression of IRF-2 arrests cells in G₂-M. These




Fig. 4. IRF-2-dependent alterations in cellular morphology of FDC-P1 cells. Cell death and polyploid morphology in IRF-2-overexpressing F2 cells. The F0 and F2 cells were cultured in the absence (-) or presence (+) of 25 ng/ml DOX for 3 days. Photographs were taken using a phase-contrast microscope with a $\times 100$ objective. Cell remnants attributable apoptosis (arrowheads) and polyploid cells (arrows) are indicated. Alterations in cellular morphology were observed only in F2 cells in which IRF-2 levels were elevated, and not in noninduced F2 cells nor in induced and noninduced F0 cells.




Fig. 5. Modulations in the level of cell cycle- and apoptosis-related factors by IRF-2 induction in FDC-P1 cells. F2 cells were cultured in complete RPMI 1640 plus IL-3-conditioned medium in the absence (-) or presence (+) of 25 ng/ml DOX. Whole-cell lysates, isolated at 1, 2, or 3 days after plating, were analyzed by Western blot with the indicated antibodies. No signal was observed for p21 (empty strip), whereas p27 levels were readily detectable; β -actin was used as control for equal protein loading.

results suggest that IRF-2 alters a mitosis-related checkpoint that may be mechanistically linked to the increase in polyploidy.

We observe that increased IRF-2 expression causes a striking elevation in the levels of the FAS-L protein that activates the FAS (Apo1/CD95) pathway (Fig. 5C). There is also a change in the ratio of the levels for the antiapoptotic Bcl-2 protein (modest decrease) and the apoptosis-promoting Bax protein (no major difference; Fig. 5C). For comparison, the levels of the tumor suppressor protein p53 remain similar in the absence or presence of DOX (Fig. 5C). Thus, the data of Fig. 5 and those presented in Fig. 4 indicate that IRF-2-induced cell death occurs concomitantly with elevation of a component of the Fas/FasL apoptotic pathway in FDC-P1 cells.

DISCUSSION

In this study, we characterized the IRF-2 oncoprotein as a component of an E2F-independent mechanism that controls cell proliferation. Our results indicate that deregulated expression of IRF-2 alters cell growth control of hematopoietic progenitor cells. We found that forced expression of IRF-2 does not affect progression through the G₁ and S phase stages of the cell cycle but alters cell growth by increasing the proportion of G₂-M cells, as well as by causing polyploidy and cell death. Cells that express IRF-2 above physiological levels exhibit increased expression of cyclin B1 and the CDK-inhibitory protein p27. Because cyclin B1 activates the mitotic CDK1(CDC2), and the p27 protein is capable of inhibiting CDK1 activity, these data indicate that cells become arrested in G₂-M. Forced expression of IRF-2 also increases the number of tetraploid cells, which implies a defect in chromosomal segregation. A subset of these cells exhibit a DNA content >4n, which indicates that cells retain competency to initiate a second round of DNA synthesis. Taken together, our findings suggest that forced expression of IRF-2 compromises a mitotic checkpoint (49), thereby creating a cell cycle defect that causes polyploidy and cell death.

Polyploidization is observed during megakaryocytic differentiation, but does not normally occur in other hematopoietic cells (50). The formation of polyploid FDCP-1 cells by forced elevation of IRF-2 levels is related to failure to undergo normal mitosis. The resulting tetraploidy may activate a p53-dependent cell cycle checkpoint in G₁ (51), and this could trigger apoptosis. However, because tetraploid IRF-2-overexpressing cells can reduplicate their genome to form polyploid (>4n) cells, these cells do not appear to arrest in G₁. Apart from p53 (52), several other transcription factors including c-Myc (53), p120E4F (54), and Trident (54) are involved in the formation of polyploid cells. For example, overexpression of the c-myc oncoprotein causes polyploidy in fibroblasts and apoptosis, and then proceeds in normal primary but not immortalized fibroblasts (53). Hence, c-myc and IRF-2 may share the ability to generate genomic instability when their expression is deregulated.

Hematopoietic stem cells represent uncommitted and undifferentiated blood cell precursors that respond to environmental signals by proliferative expansion and subsequent differentiation into mature cells. FDC-P1 cells are mouse myeloid progenitor cells that strictly depend on IL-3 for their survival. Absence of cytokines can trigger cell death in FDC-P1 cells, although there are FDC-P1 sublines that are at least partially resistant to apoptosis (55, 56). The IRF-2-dependent up-regulation of the CDK-inhibitory protein p27 in FDC-P1 cells, which occurs in parallel with increased apoptosis, could cause growth factor desensitization by interfering with the activities of CDKs (e.g., D-type cyclins and CDK4/6) that integrate growth factor-dependent signaling pathways during G₁. However, results from our cell synchronization studies with FDC-P1 cells that are blocked in G₁ reveals that competency for cell cycle progression

through G₁ and S phase occurs irrespective of elevations in IRF-2 levels. Therefore, we favor the interpretation that elevation of IRF-2 does not directly affect cytokine-dependent signaling in FDC-P1 cells.

IRF-2 may have a specific role in cell death by apoptosis. For example, IRF-2 is up-regulated during the apoptotic stage of osteoblast differentiation that occurs as a normal component of the maintenance of bone tissue organization (57). In FDC-P1 hematopoietic progenitor cells, IRF-2 may directly trigger apoptosis by regulating components of the Fas (APO-1/CD95) apoptotic pathway. Fas (APO-1/CD95) is a cell surface receptor that can mediate apoptosis and is related to the tumor necrosis factor receptor family. Cells can undergo apoptosis on expression and binding of the FasL to the Fas receptor. It has previously been shown that FasL expression in T cells is transcriptionally regulated by IRF transcription factors, and that IRF-1 and IRF-2 are each capable of interacting with the FAS-L promoter and activating FasL expression (58). Consistent with these findings, our data show that IRF-2 expression triggers a dramatic up-regulation of FasL in FDC-P1 cells, and this may activate the Fas/FasL apoptotic pathway. The product of the proto-oncogene *Bcl-2*, a membrane-associated protein, may interfere with Fas-dependent apoptosis (55, 56), and we found that overexpression of IRF-2 in FDC-P1 cells results in down-regulation of Bcl-2. Taken together, one model that can account for our findings is that the emergence of polyploidy, together with IRF-2 mediated changes in FasL levels and the concomitant activation of the FAS apoptotic pathway, may be responsible for cell death.

IRF-2 is normally up-regulated by IRF-1 in direct response to the antiproliferative actions of IFNs. Initial studies suggested that the main function of IRF-2 is to attenuate IRF-1 dependent gene activation (reviewed in Ref. 3). Our study indicates that conditional up-regulation of IRF-2 induces cell death by enhancing the endogenous levels of FasL. Hence, one important physiological function of IRF-2 is that it may extend the antiproliferative signal of IFNs by promoting conditions conducive of apoptosis. In summary, we have shown here that unbalanced expression of IRF-2 influences proliferative expansion of FDC-P1 hematopoietic progenitor cells by causing polyploidy and inducing apoptosis. Thus, our data provide important new evidence for the cell growth regulatory properties of IRF-2.

ACKNOWLEDGMENTS

We thank Cathleen Cooper for stimulating discussions and experimental assistance. We also thank Beata Paluch and Rosa Mastrototaro for technical assistance, and Judy Rask for assistance with the preparation of the manuscript.

REFERENCES

- Harada, H., Fujita, T., Miyamoto, M., Kimura, Y., Maruyama, M., Furia, A., Miyata, T., and Taniguchi, T. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. *Cell*, 58: 729–739, 1989.
- Palombella, V. J., and Maniatis, T. Inducible processing of interferon regulatory factor-2. *Mol. Cell. Biol.*, 12: 3325–3336, 1992.
- Mamane, Y., Heylbroeck, C., Genin, P., Algarte, M., Servant, M. J., LePage, C., DeLuca, C., Kwon, H., Lin, R., and Hiscott, J. Interferon regulatory factors: the next generation. *Gene*, 237: 1–14, 1999.
- Vaughan, P. S., van Wijnen, A. J., Stein, J. L., and Stein, G. S. Interferon regulatory factors: growth control and histone gene regulation—it's not just interferon anymore. *J. Mol. Med.*, 75: 348–359, 1997.
- Vaughan, P. S., Aziz, F., van Wijnen, A. J., Wu, S., Harada, H., Taniguchi, T., Soprano, K. J., Stein, J. L., and Stein, G. S. Activation of a cell-cycle-regulated histone gene by the oncogenic transcription factor IRF-2. *Nature (Lond.)*, 377: 362–365, 1995.
- Xie, R., van Wijnen, A. J., van Der, M. C., Luong, M. X., Stein, J. L., and Stein, G. S. The cell cycle control element of *histone H4* gene transcription is maximally responsive to interferon regulatory factor pairs IRF-1/IRF-3 and IRF-1/IRF-7. *J. Biol. Chem.*, 276: 18624–18632, 2001.
- van Wijnen, A. J., Ramsey-Ewing, A. L., Bortell, R., Owen, T. A., Lian, J. B., Stein, J. L., and Stein, G. S. Transcriptional element H4-site II of cell cycle regulated human

- H4 histone* genes is a multipartite protein/DNA interaction site for factors HiNF-D, HiNF-M, and HiNF-P: involvement of phosphorylation. *J. Cell Biochem.*, *46*: 174–189, 1991.
8. van Wijnen, A. J., van den Ent, F. M., Lian, J. B., Stein, J. L., and Stein, G. S. Overlapping and CpG methylation-sensitive protein-DNA interactions at the *histone H4* transcriptional cell cycle domain: distinctions between two human *H4* gene promoters. *Mol. Cell Biol.*, *12*: 3273–3287, 1992.
 9. Ramsey-Ewing, A., van Wijnen, A. J., Stein, G. S., and Stein, J. L. Delineation of a human histone H4 cell cycle element *in vivo*: the master switch for *H4* gene transcription. *Proc. Natl. Acad. Sci. USA*, *91*: 4475–4479, 1994.
 10. Vaughan, P. S., van der Meijden, C. M. J., Aziz, F., Harada, H., Taniguchi, T., van Wijnen, A. J., Stein, J. L., and Stein, G. S. Cell cycle regulation of *histone H4* gene transcription requires the oncogenic factor *IRF-2*. *J. Biol. Chem.*, *273*: 194–199, 1998.
 11. Aziz, F., van Wijnen, A. J., Vaughan, P. S., Wu, S., Shakoori, A. R., Lian, J. B., Soprano, K. J., Stein, J. L., and Stein, G. S. The integrated activities of IRF-2 (HiNF-M) CDP/cut (HiNF-D) and H4TF-2 (HiNF-P) regulate transcription of a cell cycle controlled human *histone H4* gene: mechanistic differences between distinct *H4* genes. *Mol. Biol. Rep.*, *25*: 1–12, 1998.
 12. van der Meijden, C. M. J., Vaughan, P. S., Staal, A., Albig, W., Doenecke, D., Stein, J. L., Stein, G. S., and van Wijnen, A. J. Selective expression of specific *histone H4* genes reflects distinctions in transcription factor interactions with divergent *H4* promoter elements. *Biochim. Biophys. Acta*, *1442*: 82–100, 1998.
 13. Aziz, F., van Wijnen, A. J., Stein, J. L., and Stein, G. S. HiNF-D (CDP-cut/CDC2/cyclin A/pRB-complex) influences the timing of IRF-2 dependent cell cycle activation of human *histone H4* gene transcription at the G₁/S phase transition. *J. Cell. Physiol.*, *177*: 453–464, 1998.
 14. Tanaka, N., Kawakami, T., and Taniguchi, T. Recognition DNA sequences of interferon regulatory factor 1 (IRF-1) and IRF-2, regulators of cell growth and the interferon system. *Mol. Cell Biol.*, *13*: 4531–4538, 1993.
 15. Marecki, S., Riendeau, C. J., Liang, M. D., and Fenton, M. J. PU.1 and multiple IFN regulatory factor proteins synergize to mediate transcriptional activation of the human *IL-1β* gene. *J. Immunol.*, *166*: 6829–6838, 2001.
 16. Xi, H., Goodwin, B., Shepherd, A. T., and Blanck, G. Impaired class II transactivator expression in mice lacking interferon regulatory factor-2. *Oncogene*, *20*: 4219–4227, 2001.
 17. Jesse, T. L., LaChance, R., Iademarco, M. F., and Dean, D. C. Interferon regulatory factor-2 is a transcriptional activator in muscle where it regulates expression of vascular cell adhesion molecule-1. *J. Cell Biol.*, *140*: 1265–1276, 1998.
 18. Luo, W., and Skalik, D. G. Interferon regulatory factor-2 directs transcription from the gp91phox promoter. *J. Biol. Chem.*, *271*: 23445–23451, 1996.
 19. Yamamoto, H., Lamphier, M. S., Fujita, T., Taniguchi, T., and Harada, H. The oncogenic transcription factor *IRF-2* possesses a transcriptional repression and a latent activation domain. *Oncogene*, *9*: 1423–1428, 1994.
 20. Furui, J., Uegaki, K., Yamazaki, T., Shirakawa, M., Swindells, M. B., Harada, H., Taniguchi, T., and Kyogoku, Y. Solution structure of the IRF-2 DNA-binding domain: a novel subgroup of the winged helix-turn-helix family. *Structure*, *6*: 491–500, 1998.
 21. Sharf, R., Meraro, D., Azriel, A., Thornton, A. M., Ozato, K., Petricoin, E. F., Lerner, A. C., Schaper, F., Hauser, H., and Levi, B. Z. Phosphorylation events modulate the ability of interferon consensus sequence binding protein to interact with interferon regulatory factors and to bind DNA. *J. Biol. Chem.*, *272*: 9785–9792, 1997.
 22. Birnbaum, M. J., van Zundert, B., Vaughan, P. S., Whitmarsh, A. J., van Wijnen, A. J., Davis, R. J., Stein, G. S., and Stein, J. L. Phosphorylation of the oncogenic transcription factor interferon regulatory factor 2 (*IRF2*) *in vitro* and *in vivo*. *J. Cell Biochem.*, *66*: 175–183, 1997.
 23. Masumi, A., and Ozato, K. Coactivator p300 acetylates the interferon regulatory factor-2 in U937 cells following phorbol ester treatment. *J. Biol. Chem.*, *276*: 20973–20980, 2001.
 24. Masumi, A., Wang, I. M., Lefebvre, B., Yang, X. J., Nakatani, Y., and Ozato, K. The histone acetylase PCAF is a phorbol-ester-inducible coactivator of the IRF family that confers enhanced interferon responsiveness. *Mol. Cell Biol.*, *19*: 1810–1820, 1999.
 25. Staal, A., Enserink, J. M., Stein, J. L., Stein, G. S., and van Wijnen, A. J. Molecular characterization of Celtix-1, a bromodomain protein interacting with the transcription factor interferon regulatory factor 2. *J. Cell Physiol.*, *185*: 269–279, 2000.
 26. Fujii, Y., Shimizu, T., Kusumoto, M., Kyogoku, Y., Taniguchi, T., and Hakoshima, T. Crystal structure of an IRF-DNA complex reveals novel DNA recognition and cooperative binding to a tandem repeat of core sequences. *EMBO J.*, *18*: 5028–5041, 1999.
 27. Senger, K., Merika, M., Agaloti, T., Yie, J., Escalante, C. R., Chen, G., Aggarwal, A. K., and Thanos, D. Gene repression by coactivator repulsion. *Mol. Cell*, *6*: 931–937, 2000.
 28. Schaper, F., Kirchhoff, S., Posern, G., Koster, M., Oumard, A., Sharf, R., Levi, B. Z., and Hauser, H. Functional domains of interferon regulatory factor I (IRF-1). *Biochem. J.*, *335*(Pt 1): 147–157, 1998.
 29. Lin, R., Mamane, Y., and Hiscott, J. Multiple regulatory domains control IRF-7 activity in response to virus infection. *J. Biol. Chem.*, *275*: 34320–34327, 2000.
 30. Nevins, J. R. The Rb/E2F pathway and cancer. *Hum. Mol. Genet.*, *10*: 699–703, 2001.
 31. Helin, K. Regulation of cell proliferation by the E2F transcription factors. *Curr. Opin. Genet. Dev.*, *8*: 28–35, 1998.
 32. Stein, G. S., Stein, J. L., van Wijnen, A. J., and Lian, J. B. Transcriptional control of cell cycle progression: the histone gene is a paradigm for the G₁/S phase and proliferation/differentiation transitions. *Cell Biol. Int.*, *20*: 41–49, 1996.
 33. van Wijnen, A. J., van Gorp, M. F., de Ridder, M. C., Tufarelli, C., Last, T. J., Birnbaum, M., Vaughan, P. S., Giordano, A., Krek, W., Neufeld, E. J., Stein, J. L., and Stein, G. S. CDP/cut is the DNA-binding subunit of histone gene transcription factor HiNF-D: a mechanism for gene regulation at the G₁/S phase cell cycle transition point independent of transcription factor E2F. *Proc. Natl. Acad. Sci. USA*, *93*: 11516–11521, 1996.
 34. Harada, H., Kitagawa, M., Tanaka, N., Yamamoto, H., Harada, K., Ishihara, M., and Taniguchi, T. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. *Science* (Wash. DC), *259*: 971–974, 1993.
 35. Nguyen, H., Mustafa, A., Hiscott, J., and Lin, R. Transcription factor IRF-2 exerts its oncogenic phenotype through the DNA binding/transcription repression domain. *Oncogene*, *11*: 537–544, 1995.
 36. Futaki, M., Inokuchi, K., Hanawa, H., Tanosaki, S., Dan, K., and Nomura, T. Possible transforming activity of interferon regulatory factor 2 in tumorigenicity assay of NIH3T3 cells transfected with DNA from chronic myelogenous leukemia patients. *Leuk. Res.*, *20*: 601–605, 1996.
 37. Coccia, E. M., Del Russo, N., Stellacci, E., Orsatti, R., Benedetti, E., Marziali, G., Hiscott, J., and Battistini, A. Activation and repression of the 2–5A synthetase and *p21* gene promoters by IRF-1 and IRF-2. *Oncogene*, *18*: 2129–2137, 1999.
 38. Yim, J. H., Wu, S. J., Lowney, J. K., Vander Velde, T. L., and Doherty, G. M. Enhancing *in vivo* tumorigenicity of B16 melanoma by overexpressing interferon regulatory factor-2: resistance to endogenous IFN-γ. *J. Interferon Cytokine Res.*, *19*: 723–729, 1999.
 39. Rubinstein, Y. R., Driggers, P. H., Ogryzko, V. V., Thornton, A. M., Ozato, K., and Pontzer, C. H. An IFN regulatory factor-2 DNA-binding domain dominant negative mutant exhibits altered cell growth and gene expression. *Oncogene*, *19*: 1411–1418, 2000.
 40. Lohoff, M., Duncan, G. S., Ferrick, D., Mitrucker, H. W., Bischof, S., Pechtl, S., Rollinghoff, M., Schmitt, E., Pahl, A., and Mak, T. W. Deficiency in the transcription factor interferon regulatory factor (IRF)-2 leads to severely compromised development of natural killer and T helper type 1 cells. *J. Exp. Med.*, *192*: 325–336, 2000.
 41. Hida, S., Ogasawara, K., Sato, K., Abe, M., Takayanagi, H., Yokochi, T., Sato, T., Hirose, S., Shirai, T., Taki, S., and Taniguchi, T. CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-α/β signaling. *Immunity*, *13*: 643–655, 2000.
 42. Matsuyama, T., Kimura, T., Kitagawa, M., Pfeffer, K., Kawakami, T., Watanabe, N., Kundig, T. M., Amakawa, R., Kishihara, K., Wakeham, A., and Targeted disruption of IRF-1 or IRF-2 results in abnormal type I *IFN* gene induction and aberrant lymphocyte development. *Cell*, *75*: 83–97, 1993.
 43. van Wijnen, A. J., Cooper, C., Odgren, P., Aziz, F., De Luca, A., Shakoori, R. A., Giordano, A., Quesenberry, P. J., Lian, J. B., Stein, G. S., and Stein, J. L. Cell cycle-dependent modifications in activities of pRB-related tumor suppressors and proliferation-specific CDP/cut homeodomain factors in murine hematopoietic progenitor cells. *J. Cell Biochem.*, *66*: 512–523, 1997.
 44. Shakoori, A. R., van Wijnen, A. J., Cooper, C., Aziz, F., Birnbaum, M., Reddy, G. P., Grana, X., De Luca, A., Giordano, A., Lian, J. B., Stein, J. L., Quesenberry, P., and Stein, G. S. Cytokine induction of proliferation and expression of CDC2 and cyclin A in FDC-P1 myeloid hematopoietic progenitor cells: regulation of ubiquitous and cell cycle-dependent histone gene transcription factors. *J. Cell Biochem.*, *59*: 291–302, 1995.
 45. Dexter, T. M., Garland, J., Scott, D., Scolnick, E., and Metcalf, D. Growth of factor-dependent hemopoietic precursor cell lines. *J. Exp. Med.*, *152*: 1036–1047, 1980.
 46. Cooper, C. L., Brady, G., Bilia, F., Iscove, N. N., and Quesenberry, P. J. Expression of the Id family helix-loop-helix regulators during growth and development in the hematopoietic system. *Blood*, *89*: 3155–3165, 1997.
 47. Darzynkiewicz, Z., Gong, J., and Traganos, F. Analysis of DNA content and cyclin protein expression in studies of DNA ploidy, growth fraction, lymphocyte stimulation, and the cell cycle. *Methods Cell Biol.*, *41*: 421–435, 1994.
 48. Reddy, G. P., Reed, W. C., Deacon, D. H., and Quesenberry, P. J. Growth factor-dependent proliferative stimulation of hematopoietic cells is associated with the modulation of cytoplasmic and nuclear 68-Kd calmodulin-binding protein. *Blood*, *79*: 1946–1955, 1992.
 49. Paulovich, A. G., Toczyski, D. P., and Hartwell, L. H. When checkpoints fail. *Cell*, *88*: 315–321, 1997.
 50. Brodsky, W. Y., and Uryvaeva, I. V. Cell polyploidy: its relation to tissue growth and function. *Int. Rev. Cytol.*, *50*: 275–332, 1977.
 51. Andreassen, P. R., Lohez, O. D., Lacroix, F. B., and Margolis, R. L. Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G₁. *Mol. Biol. Cell*, *12*: 1315–1328, 2001.
 52. Morgan, S. E., and Kastan, M. B. p53 and ATM: cell cycle, cell death, and cancer. *Adv. Cancer Res.*, *71*: 1–25, 1997.
 53. Li, Q., and Dang, C. V. c-Myc overexpression uncouples DNA replication from mitosis. *Mol. Cell Biol.*, *19*: 5339–5351, 1999.
 54. Rooney, R. J. Cell cycle attenuation by p120E4F is accompanied by increased mitotic dysfunction. *Cell Growth Differ.*, *12*: 505–516, 2001.
 55. Singh, N., Azmi, S., Sheriff, A., Dhawan, D., and Khanna, N. Differential sensitivity of murine myeloid FDC-P1 cells and apoptosis resistant mutant(s) to anticancer drugs. *Mutat. Res.*, *474*: 105–112, 2001.
 56. Itoh, N., Tsujimoto, Y., and Nagata, S. Effect of bcl-2 on Fas antigen-mediated cell death. *J. Immunol.*, *151*: 621–627, 1993.
 57. Lynch, M. P., Capparelli, C., Stein, J. L., Stein, G. S., and Lian, J. B. Apoptosis during bone-like tissue development *in vitro*. *J. Cell Biochem.*, *68*: 31–49, 1998.
 58. Chow, W. A., Fang, J. J., and Yee, J. K. The interferon regulatory factor family participates in regulation of *Fas ligand* gene expression in T cells. *J. Immunol.*, *164*: 3512–3518, 2000.